FMP

FMP

Enter

OBSV - ObsEva SA

photo-url-https://images.financialmodelingprep.com/symbol/OBSV.png

ObsEva SA

OBSV

NASDAQ

Inactive Equity

ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.

0.102 USD

0 (0%)

Historical Prices

From:

To:

We are unable to load the chart at this time.

fmp-logo

About

ceo

Mr. William Michael Brown

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an ...

CIK

0001685316

ISIN

CH0346177709

CUSIP

H5861P103

Address

Chemin des Aulx, 12

Phone

41 22 552 38 40

Country

CH

Employee

48

IPO Date

Jul 13, 2018

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

OBSV Financial Summary

CIK

0001685316

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

H5861P103

ISIN

CH0346177709

Country

CH

Price

0.1

Beta

0.67

Volume Avg.

7.95M

Market Cap

11M

Shares

-

52-Week

0.065-2.14

DCF

2.86

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-0.14

P/B

-

Website

https://www.obseva.com

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

Latest OBSV News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep